trending Market Intelligence /marketintelligence/en/news-insights/trending/AhLtrXmqQ4gUBhLf20qKXw2 content esgSubNav
In This List

Lixte terminates license agreement with Taipei Medical University

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Lixte terminates license agreement with Taipei Medical University

Lixte Biotechnology Holdings Inc. terminated an exclusive license agreement with Taipei Medical University, effective Dec. 25.

The termination was due to the university's failure to file and seek approval from the U.S. FDA for an investigational new drug application to treat hepatocellular carcinoma using the company's licensed technology by Dec. 25.